{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:20:11Z","timestamp":1791339611397,"version":"4.3.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Our aim was to measure the impact of two cycles of standard chemotherapy on tumoural neoangiogenesis by [<jats:sup>18<\/jats:sup>F] fluorine arginine-glycine-aspartic (RGD-K5) positron emission tomography\u2013computed tomography (PET) on patients presenting with lymphoma. Nineteen patients at Rouen\u2019s Henri Becquerel Cancer Centre were prospectively included. Fluorodeoxyglucose (FDG) and RGD-K5 PET were performed before (C0) and after (C2) two cycles of chemotherapy. End-of-treatment FDG PET was performed for final evaluation. Maximum standardised uptake value (SUVmax), SUVmean, Metabolic Tumour Volume (MTV) and Angiogenic Tumour Volume (ATV) were measured for all lesions. RGD SUVmax and SUVmean were also analysed in 13 normal organs at C0 and C2. The patient\u2019s treatment response was considered using the Deauville score (DS) at the end of FDG PET treatment (DS 1\u20133 were considered responders, and 4 and 5 non-responders).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eighteen patients had both C0 FDG and RGD PET. Twelve patients had both C2 FDG and RGD, completed the treatment protocol and were included in end-of-treatment analysis. No statistical difference was found in RGD uptake of normal organs before and after chemotherapy for SUVmax and SUVmean. On C0 RGD, apart from classical Hodgkin lymphoma (cHL; <jats:italic>n<\/jats:italic>\u2009=\u20095) and grey zone lymphoma (GZL; <jats:italic>n<\/jats:italic>\u2009=\u20091), other lymphoma sub-types (<jats:italic>n<\/jats:italic>\u2009=\u200912) had low RGD uptake (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Regarding FDG, there was no significant difference for SUVmax, SUVmean and MTV at C0 and C2 between patients with cHL and non-Hodgkin lymphoma (NHL). At C2 RGD, non-responders had higher SUVmax and SUVmean compared to responders (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). There was no significant difference in RGD ATV between responders and non-responders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study showed significant higher initial RGD uptake in patients presenting with cHL and GZL compared to NHL. Non-responder also had higher post-chemotherapy RGD uptake compared to responders. Issues raised by RGD uptake, particularly in cHL, are yet to be explored and need to be confirmed in a larger population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-021-00776-9","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T19:03:02Z","timestamp":1618254182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Angiogenesis imaging study using interim [18F] RGD-K5 PET\/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-0611","authenticated-orcid":false,"given":"David","family":"Tonnelet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D. Pierre","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Decazes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Camus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Thureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"776_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7150\/thno\/v01p0048","volume":"1","author":"AJ Beer","year":"2011","unstructured":"Beer AJ, Kessler H, Wester H-J, Schwaiger M. PET imaging of integrin \u03b1V\u03b23 expression. Theranostics. 2011;1:48\u201357.","journal-title":"Theranostics"},{"key":"776_CR2","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International working group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28:1436\u201347.","journal-title":"Ann Oncol"},{"key":"776_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1126\/science.2821619","volume":"238","author":"E Ruoslahti","year":"1987","unstructured":"Ruoslahti E, Pierschbacher M. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238:491\u20137.","journal-title":"Science"},{"key":"776_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrd819","volume":"1","author":"M Cristofanilli","year":"2002","unstructured":"Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov. 2002;1:415\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"776_CR5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s00259-018-4143-8","volume":"46","author":"L Li","year":"2019","unstructured":"Li L, Ma L, Shang D, Liu Z, Yu Q, Wang S, et al. Pretreatment PET\/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response. Eur J Nucl Med Mol Imaging. 2019;46:940\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"776_CR6","doi-asserted-by":"crossref","unstructured":"Chen S-H, Wang H-M, Lin C-Y, Chang JT-C, Hsieh C-H, Liao C-T, et al. RGD-K5 PET\/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study. Eur J Nucl Med Mol Imaging. 2016;43:1621\u20139.","DOI":"10.1007\/s00259-016-3345-1"},{"key":"776_CR7","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1007\/s00259-014-2744-4","volume":"41","author":"H-J Yoon","year":"2014","unstructured":"Yoon H-J, Kang KW, Chun IK, Cho N, Im S-A, Jeong S, et al. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET\/CT and 18F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2014;41:1534\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"776_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2967\/jnumed.107.045864","volume":"49","author":"AJ Beer","year":"2007","unstructured":"Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester H-J, et al. Comparison of integrin v 3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med. 2007;49:22\u20139.","journal-title":"J Nucl Med"},{"key":"776_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","volume":"44","author":"SF Barrington","year":"2017","unstructured":"Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44:97\u2013110.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"776_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"776_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2967\/jnumed.112.118083","volume":"54","author":"S Thureau","year":"2013","unstructured":"Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, et al. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3\u2019-Deoxy-3\u2019-18F-fluorothymidine PET images in lung cancer. J Nucl Med. 2013;54:1543\u201350.","journal-title":"J Nucl Med"},{"key":"776_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2967\/jnumed.111.088955","volume":"53","author":"M Doss","year":"2012","unstructured":"Doss M, Kolb HC, Zhang JJ, Belanger M-J, Stubbs JB, Stabin MG, et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET\/CT in monkeys and humans. J Nucl Med. 2012;53:787\u201395.","journal-title":"J Nucl Med"},{"key":"776_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1006\/scbi.2000.0327","volume":"10","author":"S Poppema","year":"2000","unstructured":"Poppema S, van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol. 2000;10:345\u201350.","journal-title":"Semin Cancer Biol"},{"key":"776_CR14","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","volume":"99","author":"BF Skinnider","year":"2002","unstructured":"Skinnider BF. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283\u201397.","journal-title":"Blood"},{"key":"776_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/path.1151","volume":"197","author":"IA Doussis-Anagnostopoulou","year":"2002","unstructured":"Doussis-Anagnostopoulou IA, Talks KL, Turley H, Debnam P, Tan DC, Mariatos G, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin\u2019s disease. J Pathol. 2002;197:677\u201383.","journal-title":"J Pathol"},{"key":"776_CR16","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3324\/haematol.2013.100818","volume":"99","author":"JF Seymour","year":"2014","unstructured":"Seymour JF, Pfreundschuh M, Trneny M, Sehn LH, Catalano J, Csinady E, et al. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014;99:1343\u20139.","journal-title":"Haematologica"},{"key":"776_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/CJI.0b013e3181a25daf","volume":"32","author":"KS Reiners","year":"2009","unstructured":"Reiners KS, Gossmann A, von Strandmann EP, B\u00f6ll B, Engert A, Borchmann P. Effects of the Anti-VEGF Monoclonal Antibody Bevacizumab in a Preclinical Model and in Patients With Refractory and Multiple Relapsed Hodgkin Lymphoma. J Immunother. 2009;32:508\u201312.","journal-title":"J Immunother"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00776-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-021-00776-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00776-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T19:06:24Z","timestamp":1618254384000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-021-00776-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1186\/s13550-021-00776-9","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This prospective study was approved by the North-west Committee for the Protection of Persons (ref CPP 02\/008\/2014). The EudraCT number is 2015\u2013000757-20 and the National Clinical Trial identifier is NCT02490891. All patients signed written consent prior to inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}